Results 71 to 80 of about 1,087 (181)

Table1_Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database.XLS

Objective:This study aims to analyze adverse drug events (ADEs) associated with cenobamate from the FAERS database, covering the third quarter of 2020 to the second quarter of 2023.Methods:Data related to cenobamate-associated ADEs from the third quarter
Huiqin Xu (1459831), Wenqiang Fang (16558371), Linqian Zhao (18158284), Shihao Chen (304374)   +3 more
core   +1 more source

Critical Appraisal of Cenobamate as Adjunctive Treatment of Focal Seizures in Adults

Neuropsychiatric Disease and Treatment, 2021
Gaetano Zaccara,1 Simona Lattanzi,2 Antonio Leo,3 Emilio Russo3 1Regional Health Agency of Tuscany, Firenze, Italy; 2Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy; 3Science of Health ...
Zaccara G, Lattanzi S, Leo A, Russo E
doaj  

Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom

Epilepsia Open
Objective Investigate real‐world outcomes in drug‐resistant epilepsy (DRE) patients treated with cenobamate as adjunctive treatment to other antiseizure medications (ASMs) within the Early Access Programs (EAP) in Germany, France, and the United Kingdom.
Sylvain Rheims, Bernhard J. Steinhoff, Edouard Hirsch, Felix Rosenow, Arnaud Biraben, Rhys Thomas, Alessandro Lovera, Paola Lipone, Alessandro Comandini, Caroline Benoist, Elena Alvarez Baron, John Paul Leach, Karthinathan Thangavelu, Agnese Cattaneo   +13 more
doaj   +1 more source

Cenobamate for Status Epilepticus: A Systematic Review

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
ABSTRACT Background: Status epilepticus (SE) is a neurologic emergency characterized by prolonged or recurrent seizures leading to significant secondary brain injury, complications, morbidity and mortality.
Moses Mo, Anna Howard, Natalia Jaworska, Caralyn Bencsik, Ish Bains, Julie Anne Kromm   +5 more
openaire   +2 more sources

Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study [PDF]

, 2022
Objective: This post hoc analysis of 10 US study sites from a long-term open-label phase 3 study of adjunctive cenobamate evaluated the efficacy of cenobamate in patients with prior epilepsy-related surgery.
Aboumatar, Sami, Sperling, Michael R, Klein, Pavel, Rosenfeld, William E, Krauss, Gregory L, Abou-Khalil, Bassel   +5 more
core  

Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug–Drug Interactions and Tolerability

, 2021
Cenobamate is one of the latest antiseizure medications (ASMs) developed for the treatment of focal onset seizures in adult patients. The recommended starting dose is 12.5 mg/day, titrated gradually to the target daily dose of 200 mg, which may be ...
Roberti R., Russo E., Iannone L. F., Lattanzi S., Zaccara G., De Caro C., Zaccara, Gaetano, Iannone, Luigi Francesco, Roberta Roberti, Carmen De Caro, Simona Lattanzi, Gaetano Zaccara, Luigi Francesco Iannone, Emilio Russo   +13 more
core   +1 more source

Cenobamate, a New Promising Antiseizure Medication: Experimental and Clinical Aspects

About 40–50% of patients with drug-resistant epilepsy do not properly respond to pharmacological therapy with antiseizure medications (ASMs). Recently approved by the US Food and Drug Administration and European Medicines Agency as an add-on drug ...
Barbara Błaszczyk, Stanisław J. Czuczwar, Barbara Miziak   +2 more
core   +1 more source

Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands

OBJECTIVE: To assess the cost-effectiveness of cenobamate in epileptic people with focal seizures in the Netherlands. METHODS: A Markov model was used to simulate lifetime costs and quality-adjusted life years (QALYs) for cenobamate compared to ...
Rijkers, Kim, Evers, Silvia; id_orcid, Lazeron, Richard, Hiligsmann, Mickaël, Klarenbeek, Pim, Laskier-Owens, Vicki, Rouhl, Rob, Li, Nannan, Majoie, Marian, Gubler, Felix   +9 more
core   +1 more source

Cenobamate reduces epileptiform activity in the ex vivo F98 rat glioma model

Frontiers in Neuroscience
IntroductionEpileptic seizures are a common clinical sign in patients suffering from high-grade glioma. In addition to therapeutic interventions aiming to prolong the remaining lifespan, maintaining quality of life is a cornerstone of current treatment ...
Ferdinand Forberger, Fabiana Santana Kragelund, Katrin Porath, Rüdiger Köhling, Rüdiger Köhling, Timo Kirschstein, Timo Kirschstein, Falko Lange, Falko Lange   +8 more
doaj   +1 more source

Efficacy of add‐on Cenobamate treatment in refractory epilepsy due to Rasmussen's encephalitis

Epilepsia Open
Objective To assess antiseizure effects of cenobamate, a new antiseizure medication with at least two mechanisms of action, in the rare, highly pharmacoresistant and progressive epilepsy syndrome related to Rasmussen's encephalitis.
Andres Schulze‐Bonhage, Bernhard Steinhoff, Mercedes Garcés, Martin Hirsch, Vicente Villanueva   +4 more
doaj   +1 more source